Medical Device News Magazine

Copper Could Help Create Clearer MRI Images and Improved Diagnosis – Study

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design, that could help to create better images that help doctors diagnose patients’ conditions more easily and safely.

Researchers discovered a novel copper protein binding site, which does not occur in nature, that has real potential for use in MRI contrast agents used to improve the visibility of internal body structures in scans.

The discovery overturns conventional medical wisdom that copper is unsuitable for use in MRI contrast agents and could help to develop new imaging agents with potentially fewer risks and side effects than exist with current commonly used contrast agents.

Researchers from the Universities of Birmingham and St Andrews, as well as Diamond Light Source, published their findings in PNAS after creating a highly elusive abiological copper site bound to oxygen donor atoms within a protein scaffold.

The experts found that the new structure displayed highly effective levels of relaxivity – the ability of a contrast agent to influence the relaxation times of protons, which helps create clearer and more informative images during an MRI scan.

Co-author Dr Anna Peacock, Reader in Bioinorganic Chemistry at the University of Birmingham, commented: “We prepared a new-to-biology copper–binding site which shows real potential for use in contrast agents and challenges existing dogma that copper is unsuitable for use in MRI.

“Despite copper largely being disregarded for use in MRI contrast agents, our binding site was shown to display extremely promising contrast agent capabilities, with relaxivities equal and superior to the Gd(III) agents used routinely in clinical MRI. Our discovery showcases a powerful approach for accessing new tools or agents for imaging applications.”

The researchers note that imaging agents based on copper could also be used in Positron emission tomography (PET) scans, which produce detailed 3-dimensional images of the inside of the body.

Their study shows use of an artificial coiled coil to create the copper site within a protein scaffold has achieved function and performance not normally associated with copper.

“Metal sites that are not part of the repertoire of biology are vital in providing protein designers with an expanded toolbox of chemistries they can use to design new functional systems such as the promising imaging capabilities reported here,” added Dr Peacock.

“This opens up applications beyond what biology is currently capable of and showcases some of the advantages of using simple miniature protein scaffolds as a means with which we can engineer new, and maybe currently unknown, metal-binding sites.”

In MRI scanners, sections of the body are exposed to a strong magnetic field causing hydrogen nuclei of water in tissues to be polarised in the direction of the magnetic field. The magnitude of the spin polarisation detected is used to form the MR image but decays with a characteristic time constant known as the T1 relaxation time.

Water protons in different tissues have different T1 values, which is one of the main sources of contrast in MR images. A contrast agent usually shortens, but in some instances increases, the value of T1 of nearby water protons – altering contrast in the image and improving the visibility of internal body structures, with the most used compounds being gadolinium-based contrast agents (GBCAs).

Gadolinium (in the form of Gd3+) is often used as a contrast agent, but there are environmental and patient safety concerns making exploration of new contrast agents an important and active research area. Although more work needs to be done to secure the stability of this new copper protein site, the study authors believe their work is a promising first step towards designing new copper-based contrast agents for clinical MRI scanning.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”